ArticleCurrent oncology reports2013
Cabozantinib as a novel therapy for renal cell carcinoma.
Article in Current oncology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.Cancer chemotherapy and pharmacology · 2015Trial
- Cabozantinib-related pneumothorax in responsive patients with renal cell carcinoma: a case report.Journal of medical case reports · 2026Article
- Quinoline Synthesis: Nanocatalyzed Green Protocols-An Overview.ACS omega · 2024Review
- Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.BioMed research international · 2018Review
- Cabozantinib for the treatment of kidney cancer.Expert review of anticancer therapy · 2017Review
- DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.International journal of oncology · 2017Article
- Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.Pharmacological research · 2017Article
- Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Current treatment options in oncology · 2017Review
- The Receptor Tyrosine Kinase AXL in Cancer Progression.Cancers · 2016Review
- Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.OncoTargets and therapy · 2016Review
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.Clinical genitourinary cancer · 2015Article
- New agents in renal cell carcinoma.Targeted oncology · 2014Review
- Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.Clinical & experimental metastasis · 2014Article
- Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib.Patient preference and adherence · 2014Review
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.BioMed research international · 2014Review
- Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.Journal of nanomedicine & nanotechnology · 2013Article
- Does a reasonable treatment approach beyond second-line exist?EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2013Review
- An update on current management of advanced renal cell cancer, biomarkers, and future directions.Annals of cancer researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cabozantinib/XL184 (Exelexis, Inc.) has demonstrated remarkable responses in kidney cancer. Preclinical results revealed VEGF, KIT and MET inhibition in a variety of solid tumors such as thyroid, ovarian, renal, lung, liver and prostate cancers. A phase II trial demonstrated efficacy in renal cancer with a 28 % objective response rate, stable disease rate of 62 % and median progression free survival of 14.7 months. Predominant toxicities of fatigue and diarrhea were noted. Dramatic responses in bone metastases (three of four patients) make the agent especially valuable for palliation in a disease, where presence of bone metastases is a predictor of worse survival. Cabozantinib is an emerging novel agent with promising activity in advanced kidney cancer. Randomized trials are planned in comparison with standard VEGF inhibitor therapy. Defining the role of MET overexpression would help patient selection and enrich and enhance the future evaluation of this targeted novel agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.